BRAF and neoplasm: ICB is, however, considered inefficacious for the majority of patients presenting MSS/MMR-proficient CRC, which causes low tumour antigenicity [6] and unlike the majority of metastatic microsatellite-instable/MMR-deficient CRC cases [2], often co-exists with high RAS/BRAF-driven oncogenic activity [7, 8].